Publications – Archives – 2014

The road ahead to cure Alzheimer’s Disease: Development of biological markers and neuroimaging methods for prevention trials across all stages and target populations.

J Prev Alz Dis 2014

E.U./U.S. CTAD task force on Alzheimer’s trial populations.

J Prev Alz Dis. 2014

Fully Automated Atlas-Based Hippocampal Volumetry for Detection of Alzheimer’s Disease in a Memory Clinic Setting.

J Alzheimers Dis. 2015

Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease.

JAMA Psychiatry. 2014 Aug

DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences-part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders.

Eur Arch Psychiatry Clin Neurosci. 2014 Aug 26

DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences-part 1: general aspects and paradigmatic discussion of depressive disorders.

Eur Arch Psychiatry Clin Neurosci. 2014 Aug

Memory concerns, memory performance and risk of dementia in patients with mild cognitive impairment.

PLoS One. 2014 Jul 14

Gene-wide analysis detects two new susceptibility genes for Alzheimer’s disease.

PLoS One. 2014 Jun 12

Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria.

Lancet Neurol. 2014 Jun;13

Cerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments.

J Neurol. 2014 Jun

The ε4 genotype of apolipoprotein E and white matter integrity in Alzheimer’s disease.

Alzheimers Dement. 2014 May

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease.

Alzheimers Dement. 2014 May

CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease.

Alzheimers Dement. 2014 May

The cerebrospinal fluid « Alzheimer profile »: Easily said, but what does it mean?

Alzheimers Dement. 2014 Apr 7

Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer’s disease.

J Alzheimers Dis. 2014

Fractional anisotropy changes in Alzheimer’s disease depend on the underlying fiber tract architecture: a multiparametric DTI study using joint independent component analysis.

J Alzheimers Dis. 2014

Subregional basal forebrain atrophy in Alzheimer’s disease: a multicenter study.

J Alzheimers Dis. 2014

Perspective on future role of biological markers in clinical therapy trials of Alzheimer’s disease: a long-range point of view beyond 2020.

Biochem Pharmacol. 2014 Apr

Cardiovascular disease contributes to Alzheimer’s disease: evidence from large-scale genome-wide association studies.

Neurobiol Aging. 2014 Apr

Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer’s disease.

Alzheimers Dement. 2014 Mar

Biomarkers in amyloid-β immunotherapy trials in Alzheimer’s disease.

Neuropsychopharmacology. 2014 Jan

The future of blood-based biomarkers for Alzheimer’s disease.

Alzheimers Dement. 2014 Jan

Publicités

Laisser un commentaire

Entrez vos coordonnées ci-dessous ou cliquez sur une icône pour vous connecter:

Logo WordPress.com

Vous commentez à l'aide de votre compte WordPress.com. Déconnexion / Changer )

Image Twitter

Vous commentez à l'aide de votre compte Twitter. Déconnexion / Changer )

Photo Facebook

Vous commentez à l'aide de votre compte Facebook. Déconnexion / Changer )

Photo Google+

Vous commentez à l'aide de votre compte Google+. Déconnexion / Changer )

Connexion à %s